featured
Effect of Dexamethasone on Days Alive and Ventilator–Free in Patients With Moderate or Severe ARDS and COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Association Between Use of Systemic Corticosteroids and Mortality in Critically Ill Patients With COVID-19
- Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19
- Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
Disclosure statements are available on the authors' profiles:
JAMA: The Journal of the American Medical Association
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial
JAMA 2020 Sep 02;[EPub Ahead of Print], BM Tomazini, IS Maia, AB Cavalcanti, O Berwanger, RG Rosa, VC Veiga, A Avezum, RD Lopes, FR Bueno, MVAO Silva, FP Baldassare, ELV Costa, RAB Moura, MO Honorato, AN Costa, LP Damiani, T Lisboa, L Kawano-Dourado, FG Zampieri, GB Olivato, C Righy, CP Amendola, RML Roepke, DHM Freitas, DN Forte, FGR Freitas, CCF Fernandes, LMG Melro, GFS Junior, DC Morais, S Zung, FR Machado, LCP AzevedoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.